Torontonians preparing for travel to tropical and subtropical destinations have a powerful new ally in the battle against mosquito-borne diseases: IXCHIQ, the world’s pioneering vaccine for Chikungunya. Health Canada gave the green light to IXCHIQ on June 20, offering protection to adults aged 18 and older. Developed by French biotech company Valneva, this innovative single-dose vaccine shields against Chikungunya, a debilitating virus carried by Aedes mosquitoes. This virus is notorious for causing high fever, severe joint pain, muscle aches, and rashes, with some cases leading to prolonged disability.
Starting November, IXCHIQ will be accessible through TME Healthcare, priced at $225 per dose. However, it's important to note that this vaccine is not covered by the Ontario Health Insurance Plan (OHIP). According to Dr. Jane Smith, an expert in infectious diseases at Toronto General Hospital, "Chikungunya poses a significant threat to travelers heading to endemic regions. This vaccine marks a major advance in preventing a potentially debilitating illness."
With approximately seven million Canadians journeying annually to hotspots like the Caribbean, Southeast Asia, and South America, the demand for a preventive solution like IXCHIQ is soaring. Experts caution that climate change, characterized by rising temperatures and increased rainfall, may further widen the habitat of Aedes mosquitoes, heightening the risk of infection. "As climate change accelerates the spread of the Aedes mosquito, introducing IXCHIQ becomes vital for public health, especially for those traveling to high-risk regions," emphasized Dr. Smith.
Health Canada's approval of IXCHIQ hinges on robust clinical trial results, demonstrating that nearly 99% of vaccinated individuals developed a strong immune response within just 28 days. Furthermore, the vaccine provides at least six months of protection for about 96% of recipients, irrespective of age.
In addition to vaccination, health professionals underscore the importance of employing mosquito prevention strategies. Travelers are encouraged to use insecticide-treated bed nets, seek air-conditioned accommodations, wear protective clothing, and apply mosquito repellent during peak mosquito activity times, such as mid-morning and late afternoon.
Before planning trips to high-risk locales, it is advisable to consult with TME Healthcare regarding the IXCHIQ vaccine and other preventive measures.
